Wedbush downgraded Idera Pharma from Outperform to Neutral and set a new price target of $1.00 from $8.00 previously

Barclays downgraded Idera Pharmaceuticals from Overweight to Equal-Weight and set a new price target of $2.00 from $10.00 previously

JMP Securities downgraded Idera Pharmaceuticals from Outperform to Market Perform

HC Wainwright & Co. downgraded Idera Pharmaceuticals from Buy to Neutral

JP Morgan downgraded Idera Pharmaceuticals from Overweight to Neutral

4 - Aceragen, Inc. (0000861838) (Issuer)

4 - Aceragen, Inc. (0000861838) (Issuer)

4 - Aceragen, Inc. (0000861838) (Issuer)

3/A - Aceragen, Inc. (0000861838) (Issuer)

4 - Aceragen, Inc. (0000861838) (Issuer)

3 - Aceragen, Inc. (0000861838) (Issuer)

4 - Aceragen, Inc. (0000861838) (Issuer)

4 - Aceragen, Inc. (0000861838) (Issuer)

4 - Aceragen, Inc. (0000861838) (Issuer)

3 - Aceragen, Inc. (0000861838) (Issuer)

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today announced it has completed the acquisition of Aceragen, Inc. ("Aceragen"), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments. The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advanceme

EXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020. “Tilsotolimod is the most advanced TLR-9 agonist therapy in development, and we are eagerly anticipating objective response rate and other important data from ILLUMINATE-301, our pivotal registration trial in anti-PD-1 refractory advanced melanoma, later this month,” stated Vincent Milano, Idera’s Chief Executive Officer. “I’m very proud of our team’s resiliency and tenacity as they work diligently toward that goal, as well as the ongoing work in ILLUMINATE-206,

15-12G - Aceragen, Inc. (0000861838) (Filer)

EFFECT - Aceragen, Inc. (0000861838) (Filer)

EFFECT - Aceragen, Inc. (0000861838) (Filer)

EFFECT - Aceragen, Inc. (0000861838) (Filer)

EFFECT - Aceragen, Inc. (0000861838) (Filer)

EFFECT - Aceragen, Inc. (0000861838) (Filer)

EFFECT - Aceragen, Inc. (0000861838) (Filer)

EFFECT - Aceragen, Inc. (0000861838) (Filer)

EFFECT - Aceragen, Inc. (0000861838) (Filer)

EFFECT - Aceragen, Inc. (0000861838) (Filer)

Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera") (NASDAQ:IDRA), a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the Company has changed its name and symbol to Aceragen, Inc. ("Aceragen," the "Company," "we," "us," or "our") and "ACGN". Additionally, the Company's stockholders approved the conversion into common s

EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022. "We are pleased to have completed the merger of Idera and Aceragen at the end of the third quarter, better enabling us to deliver important therapies for people living with rare diseases," stated John Taylor, Idera's Chief Executive Officer. "Our resulting cash position is expected to provide runway into Q3 2023 and fund the advancement of our pipeline, including ACG-701 and ACG-801, through important anticipated 2023 clinical

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today announced it has completed the acquisition of Aceragen, Inc. ("Aceragen"), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments. The combined cash of the two companies is expected to provide runway into Q3 2023, funding the advanceme

EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022. Second Quarter Financial Results Our cash position as of June 30, 2022 was $24.5 million. Based on our current operating plan, we anticipate that our current cash and cash equivalents will fund our operations through the one-year period subsequent to the August 9, 2022 filing date of the Quarterly Report Form 10-Q. Research and development expenses for the three months ended June 30, 2022 totaled $2.7 million, compared to $3.9 million for the same period in 20

EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," "we," and "our") (NASDAQ:IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Idera's synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early. INTRIM 1 is a randomized, double-blind, placebo-controlled Phase 2 trial among patients with localized, excised melanoma (pathological tumor stage 3-4) with no regional metastases detected and no evidence of distant metastasis. The trial involved a single, intradermal injection of 8 mg tilsoto

EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022. "We continue to preserve cash while actively pursuing new development or commercial-stage assets for Idera's portfolio," stated Vincent Milano, Idera's Chief Executive Officer. "We also continue to work with JMP Securities, a Citizens Company, our current partner and advisor on business development activities, to explore additional strategic alternatives for the Company."   First Quarter Financial Results Our cash position as of March 31, 2022 was $28.0 million

EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2021. "We are actively identifying and evaluating new development or commercial-stage assets for Idera's portfolio while we continue to preserve cash," stated Vincent Milano, Idera's Chief Executive Officer. "In addition, we have asked JMP Securities, a Citizens Company, our current partner and advisor on business development activities, to expand their current scope of work beyond acquisition or in-licensing opportunities to include additional strategi

EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," and "our") (NASDAQ:IDRA) today announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist. ILLUMINATE-206 Trial for the Treatment of Previously Treated Patients with Immunotherapy-Naïve Micro-Satellite Stable Colorectal Cancer (MSS-CRC)Preliminary data from the second 10 patients dosed in the safety cohort of ILLUMINATE-206, which involves tilsotolimod in combination with ipilimumab and nivolumab, showed a safety profile consistent with the first 10 patients in ILLUMINATE-206 and with prior studies. Eight patients had a post-baseline disease ass

EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," or "our") (NASDAQ:IDRA) today reported its financial and operational results for the third quarter ended September 30, 2021. "We are maintaining our focus on identifying new development or commercial-stage assets for Idera's portfolio and we are encouraged by the opportunities presented to us," stated Vincent Milano, Idera's Chief Executive Officer. "As a number of these prospects advance and as we continue to preserve cash, we remain optimistic in Idera's future potential." Added Mr. Milano, "Studies also continue in patients with microsatellite-stable colorectal cancer

EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera" or the "Company") (NASDAQ:IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021. "Our goal is to add new development or commercial-stage assets to Idera's portfolio, and our team is very encouraged by the high quality and quantity of opportunities we have been presented with," stated Vincent Milano, Idera's Chief Executive Officer. "Several of these prospects continue to advance, and we remain optimistic in Idera's future potential." Added Mr. Milano, "We also maintain our interest in the potential of tilsotolimod. Enrollment is complete and we continue to tr

SC 13D/A - Aceragen, Inc. (0000861838) (Subject)

SC 13D/A - Aceragen, Inc. (0000861838) (Subject)

SC 13D/A - Aceragen, Inc. (0000861838) (Subject)

SC 13D - Aceragen, Inc. (0000861838) (Subject)

SC 13G/A - Aceragen, Inc. (0000861838) (Subject)

SC 13D/A - Aceragen, Inc. (0000861838) (Subject)

SC 13D - Aceragen, Inc. (0000861838) (Subject)

SC 13D/A - IDERA PHARMACEUTICALS, INC. (0000861838) (Subject)

SC 13D/A - IDERA PHARMACEUTICALS, INC. (0000861838) (Subject)

SC 13D/A - IDERA PHARMACEUTICALS, INC. (0000861838) (Subject)

Gainers Sotera Health Company (NASDAQ:SHC) shares jumped 92% to $16.59 after the company announced its subsidiaries have reached agreements to settle the Ethylene Oxide cases pending against Sterigenics. Sterigenics will pay the company $408 million to settle the claims. Party City Holdco Inc. (NYSE:PRTY) gained 54% to $0.3193 following an Axios report suggesting The Franchise Group could be looking at acquiring the company. Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares rose 51.1% to $0.1224 after gaining 4% on Monday. VYNE Therapeutics Inc. (NASDAQ:VYNE) climbed 50.5% to $0.2892 after the company announced the first vitiligo patient was dosed in a Phase 1a/b clinical trial of VYN201

Gainers VYNE Therapeutics (NASDAQ:VYNE) shares rose 87.0% to $0.36 during Monday's after-market session. At the close, VYNE Therapeutics's trading volume reached 2.9 million shares. This is 590.3% of its average volume over the last 100 days. The company's market cap stands at $20.8 million. Clearside Biomedical (NASDAQ:CLSD) stock increased by 12.41% to $1.81. The market value of their outstanding shares is at $108.9 million. Nuwellis (NASDAQ:NUWE) shares increased by 12.01% to $10.44. Nuwellis's trading volume hit 230.9K shares by close, accounting for 92.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.5 million. First Wave BioPhar

Gainers Jasper Therapeutics (NASDAQ:JSPR) shares moved upwards by 576.1% to $3.27 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 39.7 million shares, making up 55465.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $121.0 million. Lucira Health (NASDAQ:LHDX) stock increased by 512.33% to $0.68. Trading volume for Lucira Health's stock is 119.7 million as of 12:30 EST. This is 35583.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $27.6 million. Reshape Lifesciences (NASDAQ:RSLS) shares moved upwards by 96.73% to $13.26. The cur

  On Wednesday, 258 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a market cap basis to set a new 52-week low. The smallest company by market cap to set a new 52-week low was Nuwellis (NASDAQ:NUWE). Alset (NASDAQ:AEI) shares traded down 1725.45% to reach its 52-week low, making it the biggest loser. Roku (NASDAQ:ROKU) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. The following stocks set new 52-week lows on Wednesday: Amazon.com (NASDAQ:AMZN) shares made a new 52-week low of $82.04 on Wednesday. The stock was up 0.13% for the day. Tesla (NASDAQ:TSLA) stock drifte

  Thursday's session saw 329 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Amazon.com (NASDAQ:AMZN). The smallest company on a market cap basis to set a new 52-week low was Schmitt Industries (NASDAQ:SMIT). Remark Hldgs (NASDAQ:MARK)'s stock made the biggest move downwards, diving 836.07% to reach a new 52-week low. Personalis (NASDAQ:PSNL)'s stock made the biggest bounce back, actually moving up 0.0% shortly after hitting a new 52-week low. Here is a list of stocks that set new 52-week lows on Thursday: Amazon.com (NASDAQ:AMZN) shares reached a new 52-week low of $84.07 on Thursday mor

  On Thursday, 241 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Tesla (NASDAQ:TSLA). Versus Systems (NASDAQ:VS) was the smallest company by market cap to set a new 52-week low. Third Harmonic Bio (NASDAQ:THRD)'s stock traded down the lowest, falling 75.68% to reach a new 52-week low. VirTra (NASDAQ:VTSI) saw the sharpest rebound, as shares ascended 0.0%, reversing after hiting a new 52-week low. On Thursday, the following stocks hit new 52-week lows: Tesla (NASDAQ:TSLA) stock hit a new 52-week low of $153.28. The stock was up 1.08% on the session. M&T Bank (NYSE:MTB) shares moved dow

Idera Pharmaceuticals (NASDAQ:IDRA) reported quarterly losses of $(0.06) per share. This is a 45.45 percent increase over losses of $(0.11) per share from the same period last year.

-SEC Filing

Gainers Senti Biosciences, Inc. (NASDAQ:SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. Golden Sun Education Group Limited (NASDAQ:GSUN) gained 39.6% to $39.76. BigBear.ai Holdings, Inc. (NYSE:BBAI) surged 36% to $1.6186 after the company announced it was awarded a $14.8 million U.S. Army Global Force Information Management system contract. Motus GI Holdings, Inc. (NASDAQ:MOTS) shares gained 29.4% to $3.0276 after the company was recognized as a sole source provider by the Veterans Health Administration. Aditxt, Inc. (NASDAQ:ADTX) shares gained 22.4% to $3.7457. Aditxt said it has regained compliance wi